Off-target effects of psychoactive drugs revealed by genome-wide assays in yeast

PLoS Genetics

Volumn 4, Issue 8, 2008, Pages

  Ericson, Elke ^a,b   Gebbia, Marinella ^a,b   Heisler, Lawrence E ^a,b   Wildenhain, Jan ^c   Tyers, Mike ^b,c,d   Giaever, Guri ^a,b   Nislow, Corey ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; 1 [2 (4 FLUOROBENZAMIDO)ETHYL] 4 (7 METHOXY 1 NAPHTHYL)PIPERAZINE; 1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; 1 [3 FLUORO 5 (3 PYRIDYL)PHENYLCARBAMOYL] 5 METHOXY 6 TRIFLUOROMETHYLINDOLINE; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 2 [[2 (2,6 DIMETHOXYPHENOXY)ETHYL]AMINOMETHYL] 1,4 BENZODIOXAN; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 (1 ADAMANTYL) 1 AMINOMETHYL 3,4 DIHYDRO 5,6 DIHYDROXY 1H 2 BENZOPYRAN; 3 [4 (3 CHLOROPHENYL) 1 PIPERAZINYL] 1,1 DIPHENYL 2 PROPANOL; 4 CARBOXY 2 METHYLPHENYLGLYCINE; 4,6,6A,7,8,12B HEXAHYDRO 7 METHYLINDOLO[4,3 AB]PHENANTHRIDINE; 5 FLUOROWILLARDIINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; 6 NITROQUIPAZINE; BEMESETRON; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CGP 78608; CHLORO KYNURENIC ACID; CLOBENPROPIT; CLOMIPRAMINE; CLOZAPINE; CYPROHEPTADINE; FLUOXETINE; FLUVOXAMINE; GLEMANSERIN; HALOPERIDOL; IMETIT; INDATRALINE; IODOPHENPROPIT; L 741741; L 741742; METERGOLINE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; NORCLOZAPINE; PAROXETINE; PIMOZIDE; PSYCHOTROPIC AGENT; RS 39604; SALMETEROL; SB 216641; SERTRALINE; SKF 83822; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANOXERINE; WAY 629; ZARDAVERINE; SACCHAROMYCES CEREVISIAE PROTEIN;

ARTICLE; CELL FUNCTION; CELL POLARITY; CHROMATIN STRUCTURE; CONTROLLED STUDY; FUNGUS GROWTH; GENE DELETION; GENOME ANALYSIS; GENOTYPE; NONHUMAN; PHARMACOGENETICS; PROTEIN FOLDING; RNA GENE; RNA PROCESSING; SACCHAROMYCES CEREVISIAE; YEAST; DNA MICROARRAY; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION PROFILING; GENETICS; GENOME; GROWTH, DEVELOPMENT AND AGING; HUMAN; LIPID METABOLISM; METABOLISM; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; TELOMERE;

SACCHAROMYCES CEREVISIAE; SACCHAROMYCETALES;

CELL POLARITY; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENOME, FUNGAL; HUMANS; LIPID METABOLISM; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN BIOSYNTHESIS; PROTEIN TRANSPORT; PSYCHOTROPIC DRUGS; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; TELOMERE;

EID: 50849097234     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1000151     Document Type: Article

References (52)

1. WHO (2001) World Health report. Geneva.
2. Arana GW (2000) An overview of side effects caused by typical antipsychotics. J Clin Psychiatry 61 Suppl 8: 5-11; discussion 12-13.
3. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA (1993) Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 329: 162-167.
4. Merrill DB, Ahmari SE, Bradford JM, Lieberman JA (2006) Myocarditis during clozapine treatment. Am J Psychiatry 163: 204-208.
5. Varambally S, Howpage P (2007) Acute myocarditis associated with clozapine. Australas Psychiatry 15: 343-346.
6. Wehmeier PM, Heiser P, Remschmidt H (2005) Myocarditis, pericarditis and cardiomyopathy in patients treated with clozapine. J Clin Pharm Ther 30: 91-96.
7. Geddes J, Freemantle N, Harrison P, Bebbington P (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Bmj 321: 1371-1376.
8. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, et al. (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5: e45.
9. Melese T, Hieter P (2002) From genetics and genomics to drug discovery: yeast rises to the challenge. Trends Pharmacol Sci 23: 544-547.
10. Sturgeon CM, Kemmer D, Anderson HJ, Roberge M (2006) Yeast as a tool to uncover the cellular targets of drugs. Biotechnol J 1: 289-298.
11. Dehay B, Bertolotti A (2006) Critical role of the proline-rich region in Huntingtin for aggregation and cytotoxicity in yeast. J Biol Chem 281: 35608-35615.
12. Duennwald ML, Jagadish S, Muchowski PJ, Lindquist S (2006) Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad Sci U S A 103: 11045-11050.
13. Giorgini F, Guidetti P, Nguyen Q, Bennett SC, Muchowski PJ (2005) A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet 37: 526-531.
14. Gokhale KC, Newnam GP, Sherman MY, Chernoff YO (2005) Modulation of prion-dependent polyglutamine aggregation and toxicity by chaperone proteins in the yeast model. J Biol Chem 280: 22809-22818.
15. Meriin AB, Zhang X, He X, Newnam GP, Chernoff YO, et al. (2002) Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1. J Cell Biol 157: 997-1004.
16. Outeiro TF, Lindquist S (2003) Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302: 1772-1775.
17. Solans A, Zambrano A, Rodriguez M, Barrientos A (2006) Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III. Hum Mol Genet 15: 3063-3081.
18. Willingham S, Outeiro TF, DeVit MJ, Lindquist SL, Muchowski PJ (2003) Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science 302: 1769-1772.
19. Duennwald ML, Jagadish S, Giorgini F, Muchowski PJ, Lindquist S (2006) A network of protein interactions determines polyglutamine toxicity. Proc Natl Acad Sci U S A 103: 11051-11056.
20. Baetz K, McHardy L, Gable K, Tarling T, Reberioux D, et al. (2004) Yeast genome-wide drug-induced haploinsufficiency screen to determine drug mode of action. Proc Natl Acad Sci U S A 101: 4525-4530.
21. Brown JA, Sherlock G, Myers CL, Burrows NM, Deng C, et al. (2006) Global analysis of gene function in yeast by quantitative phenotypic profiling. Mol Syst Biol 2: 2006 0001.
22. Giaever G, Flaherty P, Kumm J, Proctor M, Nislow C, et al. (2004) Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc Natl Acad Sci U S A 101: 793-798.
23. Hillenmeyer ME, Fung E, Wildenhain J, Pierce SE, Hoon S, et al. (2008) The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science 320: 362-365.
24. Lee W, St Onge RP, Proctor M, Flaherty P, Jordan MI, et al. (2005) Genome-Wide Requirements for Resistance to Functionally Distinct DNA-Damaging Agents. PLoS Genet 1: e24.
25. Lum PY, Armour CD, Stepaniants SB, Cavet G, Wolf MK, et al. (2004) Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 116: 121-137.
26. Parsons AB, Lopez A, Givoni IE, Williams DE, Gray CA, et al. (2006) Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell 126: 611-625.
27. Giaever G, Chu AM, Ni L, Connelly C, Riles L, et al. (2002) Functional profiling of the Saccharomyces cerevisiae genome. Nature 418: 387-391.
28. Shoemaker DD, Lashkari DA, Morris D, Mittmann M, Davis RW (1996) Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar-coding strategy. Nat Genet 14: 450-456.
29. Winzeler EA, Shoemaker DD, Astromoff A, Liang H, Anderson K, et al. (1999) Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 285: 901-906.
30. Giaever G, Shoemaker DD, Jones TW, Liang H, Winzeler EA, et al. (1999) Genomic profiling of drug sensitivities via induced haploinsufficiency. Nat Genet 21: 278-283.
31. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46: 3-26.
32. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863-14868.
33. Askree SH, Yehuda T, Smolikov S, Gurevich R, Hawk J, et al. (2004) A genome-wide screen for Saccharomyces cerevisiae deletion mutants that affect telomere length. Proc Natl Acad Sci U S A 101: 8658-8663.
34. Gatbonton T, Imbesi M, Nelson M, Akey JM, Ruderfer DM, et al. (2006) Telomere length as a quantitative trait: genome-wide survey and genetic mapping of telomere length-control genes in yeast. PLoS Genet 2: e35.
35. Hao S, Sharp JW, Ross-Inta CM, McDaniel BJ, Anthony TG, et al. (2005) Uncharged tRNA and sensing of amino acid deficiency in mammalian piriform cortex. Science 307: 1776-1778.
36. Harata M, Mochizuki R, Mizuno S (1999) Two isoforms of a human actin-related protein show nuclear localization and mutually selective expression between brain and other tissues. Biosci Biotechnol Biochem 63: 917-923.
37. Valpuesta JM, Martin-Benito J, Gomez-Puertas P, Carrascosa JL, Willison KR (2002) Structure and function of a protein folding machine: the eukaryotic cytosolic chaperonin CCT. FEBS Lett 529: 11-16.
38. Masellis M, Basile VS, Ozdemir V, Meltzer HY, Macciardi FM, et al. (2000) Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biol Psychiatry 47: 252-266.
39. Bull LN, van Eijk MJ, Pawlikowska L, DeYoung JA, Juijn JA, et al. (1998) A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet 18: 219-224.
40. Bouhouche A, Benomar A, Bouslam N, Chkili T, Yahyaoui M (2006) Mutation in the epsilon subunit of the cytosolic chaperonin-containing t-complex peptide-1 (Cct5) gene causes autosomal recessive mutilating sensory neuropathy with spastic paraplegia. J Med Genet 43: 441-443.
41. Bourke GJ, El Alami W, Wilson SJ, Yuan A, Roobol A, et al. (2002) Slow axonal transport of the cytosolic chaperonin CCT with Hsc73 and actin in motor neurons. J Neurosci Res 68: 29-35.
42. Abdel-Halim MN, Yousufazai SYK (1981) Physiological mechanism by which acetyl CoA carboxylase is regulated Cellular and Molecular Life Sciences 37: 1167-1168.
43. Pangalila-Ratu Langi EA, Jansen AAI (1988) Ritanserin in the Treatment of Generalized Anxiety Disorders: A Placebo-controlled Trial. Human Psychopharmacology 3: 207-212.
44. Brachmann CB, Davies A, Cost GJ, Caputo E, Li J, et al. (1998) Designer deletion strains derived from Saccharomyces cerevisiae S288C: a useful set of strains and plasmids for PCR-mediated gene disruption and other applications. Yeast 14: 115-132.
45. Sherman F (1991) Guide to Yeast Genetics and Molecular Biology; Guthrie C, Fink GR, eds. San Diego: Academic Press, Inc.
46. Onge RP, Mani R, Oh J, Proctor M, Fung E, et al. (2007) Systematic pathway analysis using high-resolution fitness profiling of combinatorial gene deletions. Nat Genet.
47. Pierce SE, Davis RW, Nislow C, Giaever G (2007) Genome-wide analysis of barcoded Saccharomyces cerevisiae gene-deletion mutants in pooled cultures. Nat Protoc 2: 2958-2974.
48. Pierce SE, Fung EL, Jaramillo DF, Chu AM, Davis RW, et al. (2006) A unique and universal molecular barcode array. Nat Methods 3: 601-603.
49. Falcon S, Gentleman R (2007) Using GOstats to test gene lists for GO term association. Bioinformatics 23: 257-258.
50. Saeed AI, Sharov V, White J, Li J, Liang W, et al. (2003) TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34: 374-378.
51. Hassan M, Brown RD, Varma-O'brien S, Rogers D (2006) Cheminformatics analysis and learning in a data pipelining environment. Mol Divers 10: 283-299.
52. Ghose AK, Viswanadhan VN, Wendoloski JJ (1999) A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1: 55-68.